May 10 (Reuters) - The U.S. Food and Drug Administration

has pushed back its decision on Moderna's ( MRNA ) respiratory

syncytial virus (RSV) vaccine by more than two weeks to the end

of this month due to some "administrative constraints", the

company said on Friday.

The FDA's move prolongs the wait for Moderna's ( MRNA ) second

approved product, but the company said it remains on track to be

reviewed by a panel of advisers at the U.S. Centers for Disease

Control and Prevention (CDC) on June 26 and 27.

The CDC panel is expected to vote on recommendations for the

vaccine's use and the intended population at the meeting, and

success there is necessary for commercial launch.

Cambridge, Massachusetts-based Moderna ( MRNA ) has been banking on

its experimental shots to make up for vastly lower sales of its

Spikevax COVID vaccine, its only marketed product, after the

pandemic.

(Reporting by Patrick Wingrove and Leroy Leo in Bengaluru;

Editing by Shinjini Ganguli)